Clinical Trial Update: Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effects of intact GLP-1 (7-36) and GLP-1 metabolite (9-36) on coronary and peripheral vascular function in adults with coronary m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Microvascular Dysfunction

Drugs mentioned

• GLP-1 (7-36) (glucagon-like peptide-1 (GLP-1) intact peptide)
• GLP-1 metabolite (9-36) (GLP-1 metabolite)

Snippet

Sponsor: Mette Zander | Conditions: Coronary Microvascular Dysfunction | Phase 4 | Status: COMPLETED